Engineered immune cells take on Hard-to-Treat sarcomas in first human test

NCT ID NCT07052383

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcomas that have stopped responding to standard treatments. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are to check safety, find the highest safe dose, and see if the treatment can slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DIT309 cell injection (CAR-T cells)
What this could lead to
If it works, this could point toward a new treatment option for advanced sarcomas that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 15 participants, so it is primarily testing safety and dosing. The therapy may not shrink tumors or could cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai General Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.